Through the years, LETI Pharma has demonstrated its capacity for innovation and entrepreneurship.
- First pharmaceutical company to produce penicillin in Spain and possibly in Continental Europe.
- First and only pharmaceutical company approved by the World Health Organization to produce influenza vaccine in Spain.
- Pioneer in the production of therapeutic vaccines for allergy.
- Introduced pregnancy tests, medicated toothpastes, medicated shaving foam, syndets and pH5.5 for skin care and hygiene in Spain.
1919 Dr. Domingo creates Laboratorio Experimental de Terapéutica Inmunógena (LETI) -- Laboratory of Experimental Immunogenic Therapeutics
1941 LETI Allergy Service begins production of allergenic extracts for diagnosis and treatment
1946 First industrial production of penicillin in Continental Europe: Penicillin L-U (LETI - UQUIFA)
1949 Incorporation of Antibióticos S.A. (of the six partners only LETI and Zeltia remain)
1960 Production of the first influenza vaccine in Spain
1985 Start of Leishmania Research Program (All- Inn)
1992 New Allergy plant and R&D laboratory in Tres Cantos (Madrid)
Creation of LETI Portugal
1998 Patent of Q Protein for Leishmaniasis vaccine
1999 Patent and launch of Depigoid for treatment of allergies
Launch of first Leti Test diagnosis
2000 Creation of LETI Germany
Launch of LETIAT4 and LetiBalm
2007 Launch of TOLforte
2008 Launch of LetiSR
2010 Launch of LetiXer
The canine vaccine completes Phase III and obtains EMA MUMS (“Minor Use for a Major Species”) status
2013 Launch of DepigoidDUO and DepigoidOptimizado
Entrance to North American market (Dermworx)
Acquisition of UNIVET
2017 Launch of LetiFend®
The first vaccine against canine leishmaniasis developed in Europe based on a recombinant protein.